IBI321
Sponsors
Innovent Biologics (Suzhou) Co. Ltd.
Conditions
Advanced Solid Tumors
Phase 1
A Study of Dose Escalation of IBI321 in Patients With Advanced Solid Tumors
CompletedNCT04911894
Start: 2021-06-21End: 2023-02-17Updated: 2023-03-01
A Study of the Safety and Tolerability of IBI321 in Patients With Advanced Solid Tumors
CompletedNCT04911881
Start: 2021-06-24End: 2023-02-23Updated: 2023-03-01
A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors
NCT05172856
Start: 2022-03-01End: 2024-12-31Target: 110Updated: 2021-12-29